Investigational drug · Phase 2
SRP-1003
Also called: ARO-DM1
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Myotonic Dystrophy 1.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "SRP-1003"
First trial start
2024
Mar 4, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SRP-1003", any sponsor or status.
Conditions studied
As listed on its trial records.
- Myotonic Dystrophy 1
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "SRP-1003" as an intervention, largest first.
- Study of SRP-1003 in Participants With Type 1 Myotonic DystrophyEnrolling by invitation
Sarepta Therapeutics, Inc.Industry
NCT06138743 · 78 participants (planned) · Start Mar 4, 2024 · Primary completion Dec 31, 2026
Drug: SRP-1003 IV Infusion; Placebo IV Infusion and 2 more · For: Myotonic Dystrophy 1
Sites: Liverpool, Australia; Birtinya, Australia; Herston, Australia · 35 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Myotonic Dystrophy 1
- Del-desiranAOC 1001Phase 33 trials
Avidity Biosciences, Inc. · DM1, Myotonic Dystrophy, Myotonic Dystrophy 1
- PGN-EDODM1Phase 22 trials
PepGen Inc · Myotonic Dystrophy 1
- ATX-01Phase 21 trial
ARTHEx Biotech S.L. · Myotonic Dystrophy 1
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.